Bio-Path Holdings, Inc.
BPTH · OTC · United States
Share price · BPTH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BPTH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Jun 2026+66.7%
Nothing announced by BPTH that day or the session before.
- 5 Jun 2026+33.3%
Nothing announced by BPTH that day or the session before.
- 1 Jun 2026+33.3%
Nothing announced by BPTH that day or the session before.
- 22 May 2026+33.3%
Nothing announced by BPTH that day or the session before.
- 20 May 2026+50.0%
Nothing announced by BPTH that day or the session before.
- 19 May 2026-50.0%
Nothing announced by BPTH that day or the session before.
- 15 May 2026+33.3%
- 13 May 2026-25.0%
Nothing announced by BPTH that day or the session before.
- 12 May 2026-20.0%
Nothing announced by BPTH that day or the session before.
- 8 May 2026-16.7%
Nothing announced by BPTH that day or the session before.
Share of unusual movement by asset
For each asset, the share of BPTH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | GRB2 (growth factor receptor-bound protein 2) mRNARNA / oligonucleotide | Acute Myeloid Leukemia | |
| Phase 1 | BCL2 mRNARNA / oligonucleotide | Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
Financial reports
Quarterly & interim (14)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | <$0.1M | <$0.1M | $0.3M-<$0.1M operating cash flow | report ↗ |
View 13 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | $0.3M | — | $1.0M$0 operating cash flow | report ↗ |
| 2025-Q2 | — | $4.0M | $0 | $4.6M-$0.3M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.0M | $0.1M | $2.9M-$1.3M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.3M | $0.6M | $2.1M-$3.4M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.9M | $4.0M | $1.9M-$4.3M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.3M | $0.2M | $3.2M-$1.0M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.3M | $2.4M | $3.2M-$2.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $3.0M | $3.4M | $4.2M-$3.3M operating cash flow | report ↗ |
| 2023-Q1 | — | $4.0M | $6.7M | $5.3M-$3.6M operating cash flow | report ↗ |
| 2022-Q3 | — | $2.4M | $14M | $3.5M-$3.4M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.9M | $17M | $3.0M-$4.2M operating cash flow | report ↗ |
| 2022-Q1 | — | $2.1M | $21M | $3.4M-$2.5M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.0M | $27M | $2.1M-$2.9M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $7.3M | $1.2M | $2.5M-$11M operating cash flow | report ↗ |
Bio-Path Holdings reported revenue was not disclosed for the full year 2024. R&D expense was $7.3 million, down 37.1% YoY, and cash and equivalents stood at $1.2 million. The company reported a net loss of $9.9 million, or $4.12 per share, for the year.
Bio-Path highlighted progress across its obesity and oncology programs, including preclinical results for BP1001-A in obesity and Type 2 diabetes showing restored insulin sensitivity in cell models. The company expanded its global patent portfolio with newly issued patents in the U.S. and New Zealand, and provided an update from the Phase 1/1b trial of BP1002 in refractory/relapsed acute myeloid leukemia, which has advanced to the fourth dose cohort of 90 mg/m².
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2024-07-30 | Nielsen Peter Henry · director, President, CEO & CFO | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2024-07-30 | MORRIS DOUGLAS P · director | Award / grant (derivative) | 3,537 | — | — | Form 4 |
| 2024-07-30 | Cleaver Heath · director | Award / grant (derivative) | 2,000 | — | — | Form 4 |
| 2024-07-30 | Aubert Paul · director | Award / grant (derivative) | 2,000 | — | — | Form 4 |
| 2024-07-30 | Sherwood Aline · director | Award / grant (derivative) | 2,000 | — | — | Form 4 |
| 2023-05-02 | Nielsen Peter Henry · director, President, CEO & CFO | Award / grant (derivative) | 105,000 | — | — | Form 4 |
| 2023-05-02 | MORRIS DOUGLAS P · director | Award / grant (derivative) | 13,000 | — | — | Form 4 |
| 2023-05-02 | Sherwood Aline · director | Award / grant (derivative) | 10,000 | — | — | Form 4 |